艾伯维（ABBV）今日盘中股价大幅下跌7.25%，引发了市场广泛关注。
消息面上，尽管公司预测2026年利润高于预期，但分析师指出其营收增长主要依赖传统药物Humira，而该药销售额正受到仿制药侵蚀，引发了市场对营收结构可持续性的担忧。同时，公司高管预计2026年医美业务增长仍将面临挑战，需通过投资刺激渗透率偏低的市场。
此外，公司最新公布的第四季度业绩受到收购相关无形资产研发及里程碑费用的显著拖累，这些一次性支出对每股收益造成了0.71美元的负面影响。市场对上述因素的叠加反应，共同导致了此次股价的大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.